Drug Therapy for Parkinson's Disease

ABSTRACT

The fundamental concepts of the medical treatment of Parkinson's disease are simple, and remain based on the enhancement of dopaminergic transmission by means of levodopa and dopamine agonists. Recently published practice parameters from the American Academy of Neurology and an evidence-based review under the auspices of the Movement Disorder Society provide guidance on motor complications and also cognitive and psychiatric issues associated with Parkinson's disease. The choices of medications are increasing as are the routes of administration, with the arrival of injectable and transdermal dopamine agonists and a monoamine inhibitor absorbed via the buccal mucosa. Although simple conceptually, the actual care of patients with Parkinson's disease is often complex, requiring consideration of potential future complications and individualized medication regimens, and minimizing the adverse effects of medications that range from unpleasant to seriously disturbing.

KEYWORDS

Parkinson's disease - levodopa - dopamine agonists - COMT inhibition - MAO inhibition - dyskinesias - impulse control disorder

REFERENCES

• 1 Pahwa R, Factor S A, Lyons K E et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 983-995
• 2 Miyasaki J M, Shannon K, Voon V et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 996-1002
• 3 Suchowersky O, Gronseth G, Perlmutter J et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 976-982
• 4 Onuaguluchi G. Drug treatment of parkinsonism and its assessment. In: Vinken PJ, Bruyn GW Handbook of Clinical Neurology. New York; John Wiley & Sons Inc 1968: 218-226
• 5 Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease.  Cochrane Database Syst Rev. 2003;  (2) CD003735
• 6 Perry E K, Kilford L, Lees A J, Burn D J, Perry R H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.  Ann Neurol. 2003;  54 235-238
• 7 Lloyd K G, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.  J Pharmacol Exp Ther. 1975;  195 453-464
• 8 Cotzias G C, Papavasiliou P S, Gellene R. Experimental treatment of parkinsonism with L-Dopa.  Neurology. 1968;  18 276-277
• 9 Cotzias G C, Van Woert M H, Schiffer L M. Aromatic amino acids and modification of parkinsonism.  N Engl J Med. 1967;  276 374-379
• 10 Fahn S, Oakes D, Shoulson I et al.. Levodopa and the progression of Parkinson's disease. Parkinson Study Group.  N Engl J Med. 2004;  351 2498-2508
• 11 Parkinson Study Group . Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.  Ann Neurol. 1996;  39 37-45
• 12 Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.  JAMA. 2000;  284 1931-1938
• 13 Rascol O, Brooks D J, Korczyn A D et al.. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.  N Engl J Med. 2000;  342 1484-1491
• 14 Blanchet P J, Calon F, Martel J C et al.. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.  J Pharmacol Exp Ther. 1995;  272 854-859
• 15 Bibbiani F, Costantini L C, Patel R, Chase T N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.  Exp Neurol. 2005;  192 73-78
• 16 Schrag A, Ben-Shlomo Y, Brown R et al.. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality.  Mov Disord. 1998;  13 885-894
• 17 Sato K, Hatano T, Yamashiro K et al.. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Juntendo Parkinson Study Group.  Mov Disord. 2006;  21 1384-1395
• 18 Koller W C, Hutton J T, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.  Neurology. 1999;  53 1012-1019
• 19 Calne D B, Teychenne P F, Claveria L E et al.. Bromocriptine in parkinsonism.  BMJ. 1974;  4 442-444
• 20 Holloway R G, Shoulson I, Fahn S et al.. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.  Arch Neurol. 2004;  61 1044-1053
• 21 Brunt E R, Brooks D J, Korczyn A D, Montastruc J L, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. 043 Study Group.  J Neural Transm. 2002;  109 489-502
• 22 Goetz C G, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.  Mov Disord. 2005;  20 523-539
• 23 Kurlan R. “Levodopa phobia:” a new iatrogenic cause of disability in Parkinson disease.  Neurology. 2005;  64 923-924
• 24 Van Gerpen J A, Kumar N, Bower J H, Weigand S, Ahlskog J E. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.  Arch Neurol. 2006;  63 205-209
• 25 The Parkinson Study Group . A controlled trial of rotigotine monotherapy in early Parkinson's disease.  Arch Neurol. 2003;  60 1721-1728
• 26 Stocchi F, Hersh B P, Earl N L, Scott B L. Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson's disease. Poster presentation P894, Movement Disorder Society 10th International Congress of Parkinson's Disease and Movement Disorders Kyoto, Japan; 2006
• 27 Yoshioka M, Tanaka K, Miyazaki I et al.. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.  Neurosci Res. 2002;  43 259-267
• 28 Le W D, Jankovic J, Xie W, Appel S H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.  J Neural Transm. 2000;  107 1165-1173
• 29 Frucht S, Rogers J D, Greene P E, Gordon M F, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.  Neurology. 1999;  52 1908-1910
• 30 Arnulf I, Konofal E, Merino-Andreu M et al.. Parkinson's disease and sleepiness: an integral part of PD.  Neurology. 2002;  58 1019-1024
• 31 Gjerstad M D, Alves G, Wentzel-Larsen T, Aarsland D, Larsen J P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?.  Neurology. 2006;  67 853-858
• 32 Giovannoni G, O'Sullivan J D, Turner K, Manson A J, Lees A J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.  J Neurol Neurosurg Psychiatry. 2000;  68 423-428
• 33 Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.  Neurology. 2003;  61 422-423
• 34 Pontone G, Williams J R, Bassett S S, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease.  Neurology. 2006;  67 1258-1261
• 35 Voon V, Hassan K, Zurowski M et al.. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.  Neurology. 2006;  67 1254-1257
• 36 Hunter K R, Boakes A J, Laurence D R, Stern G M. Monoamine oxidase inhibitors and L-dopa.  Br Med J. 1970;  3 388
• 37 Youdim M B, Edmondson D, Tipton K F. The therapeutic potential of monoamine oxidase inhibitors.  Nat Rev Neurosci. 2006;  7 295-309
• 38 Waters C H, Sethi K D, Hauser R A, Molho E, Bertoni J M. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Zydis Selegiline Study Group.  Mov Disord. 2004;  19 426-432
• 39 Parkinson Study Group . A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.  Arch Neurol. 2002;  59 1937-1943
• 40 Parkinson Study Group . A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.  Arch Neurol. 2005;  62 241-248
• 41 Wu R M, Murphy D L, Chiueh C C. Neuronal protective and rescue effects of deprenyl against MPP + dopaminergic toxicity.  J Neural Transm Gen Sect. 1995;  100 53-61
• 42 Youdim M B, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.  Ann NY Acad Sci. 2001;  939 450-458
• 43 Nutt J G. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.  Neurology. 2000;  55(suppl 4) S33-S37
• 44 Adler C H, Singer C, O'Brien C et al.. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.  Arch Neurol. 1998;  55 1089-1095
• 45 Parkinson Study Group . Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients.  Ann Neurol. 1997;  42 747-755
• 46 Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard P R. Tolcapone and fulminant hepatitis.  Lancet. 1998;  352 958
• 47 Schwab R S, England Jr A C, Poskanzer D C, Young R R. Amantadine in the treatment of Parkinson's disease.  JAMA. 1969;  208 1168-1170
• 48 Dallos V, Heathfield K, Stone P, Allen F A. Use of amantadine in Parkinson's disease: results of a double-blind trial.  BMJ. 1970;  4 24-26
• 49 Scotti G, Spinnler H. Amantadine and Huntington's chorea.  N Engl J Med. 1971;  285 1325-1326
• 50 Adler C H, Stern M B, Vernon G, Hurtig H I. Amantadine in advanced Parkinson's disease: good use of an old drug.  J Neurol. 1997;  244 336-337
• 51 Factor S A, Molho E S, Brown D L. Acute delirium after withdrawal of amantadine in Parkinson's disease.  Neurology. 1998;  50 1456-1458
• 52 Costa A, Peppe A, Dell'Agnello G et al.. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.  Dement Geriatr Cogn Disord. 2003;  15 55-66
• 53 Molloy S A, Rowan E N, O'Brien J T et al.. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.  J Neurol Neurosurg Psychiatry. 2006;  77 1323-1328
• 54 Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.  Neurosci Biobehav Rev. 2006;  30 1-23
• 55 Ravina B, Putt M, Siderowf A et al.. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.  J Neurol Neurosurg Psychiatry. 2005;  76 934-939
• 56 Emre M, Aarsland D, Albanese A et al.. Rivastigmine for dementia associated with Parkinson's disease.  N Engl J Med. 2004;  351 2509-2518
• 57 Hyson H C, Johnson A M, Jog M S. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.  Mov Disord. 2002;  17 1318-1320
• 58 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo M G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.  Mov Disord. 2006;  21 704-707
• 59 Senard J M, Brefel-Courbon C, Rascol O, Montastruc J L. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.  Drugs Aging. 2001;  18 495-505
• 60 Singer W, Sandroni P, Opfer-Gehrking T L et al.. Pyridostigmine treatment trial in neurogenic orthostatic hypotension.  Arch Neurol. 2006;  63 513-518
• 61 Singer W, Opfer-Gehrking T L, Nickander K K, Hines S M, Low P A. Acetylcholinesterase inhibition in patients with orthostatic intolerance.  J Clin Neurophysiol. 2006;  23 476-481
• 62 Winge K, Fowler C J. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.  Mov Disord. 2006;  21 737-745
• 63 Zesiewicz T A, Helal M, Hauser R A. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease.  Mov Disord. 2000;  15 305-308